On 12 December 2017, orphan designation (EU/3/17/1947) was granted by the European Commission to NeuroVive Pharmaceutical AB, Sweden, for 2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione (also known as KL1333) for the treatment of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes.
In January 2021, NeuroVive Pharmaceutical AB changed name to Abliva AB.
EU/3/17/1947: Public summary of opinion on orphan designation: 2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione for the treatment of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (PDF/127.2 KB)
First published: 23/01/2018
Last updated: 23/01/2018
|Disease / condition||
Treatment of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.